CRNX Crinetics
- 44.290
- -0.420-0.94%
- 44.990
- +0.700+1.58%
Crinetics News
Express News | Ey Announces Scott Struthers, Ph.d., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur of the Year® 2024 Pacific Southwest Award Winner
Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...
Crinetics(CRNX.US) Officer Sells US$131.58K in Common Stock
$Crinetics(CRNX.US)$ Officer Betz Stephen F. sold 3,000 shares of common stock on Jun 10, 2024 at an average price of $43.86 for a total value of $131.58K.Source: Announcement What is statement of cha
Express News | Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Form 144 | Crinetics(CRNX.US) Officer Proposes to Sell 131.58K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 10, $Crinetics(CRNX.US)$ Officer Betz Stephen F. intends to sell 3,000 shares of its common stock on Jun 10, with a total market value of approximately $131.58K. Betz Ste
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $60 to $80
On Jun 04, major Wall Street analysts update their ratings for $Crinetics(CRNX.US)$, with price targets ranging from $60 to $80.Morgan Stanley analyst Jeffrey Hung maintains with a buy rating, and mai
Express News | Crinetics Pharmaceuticals : Oppenheimer Raises Target Price to $74 From $55
Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Keybanc cut
Crinetics Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Crinetics Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Crinetics Pharmaceuticals Price Target Raised to $74.00/Share From $55.00 by Oppenheimer
Crinetics Pharmaceuticals Price Target Raised to $74.00/Share From $55.00 by Oppenheimer
17 Analysts Have This To Say About Crinetics Pharmaceuticals
In the latest quarter, 17 analysts provided ratings for Crinetics Pharmaceuticals (NASDAQ:CRNX), showcasing a mix of bullish and bearish perspectives.The table below provides a concise overview of rec
Express News | HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $60 Price Target
Crinetics Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 29.65% HC Wainwright & Co. $60 → $60 Reiterates Buy → Buy 05/23/2024 29.65% HC Wainwright & Co.
Express News | Crinetics Pharmaceuticals Inc - Toucahn Study Is Ongoing, With Topline Results From Complete Study Expected in Second Half of 2024
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced initial findings from the development program of its second clinical product candidate, atumelnant* (CRN04894), a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist.
Crinetics Presents New Data at ENDO 2024 That Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine New PATHFNDR-1
Express News | Crinetics Announces Positive Initial Findings at Endo 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (Cah) and Acth-Dependent Cushing’s Syndrome (Adcs)
Shareholders Will Probably Not Have Any Issues With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...
Crinetics(CRNX.US) Officer Sells US$142.47K in Common Stock
$Crinetics(CRNX.US)$ Officer Betz Stephen F. sold 3,000 shares of common stock on May 28, 2024 at an average price of $47.49 for a total value of $142.47K.Source: Announcement What is statement of cha
Analysis
Price Target
No Data
